Safety, Efficacy and Pharmacokinetics (PK) Study of WR 279,396 Versus Paromomycin for Treatment of Cutaneous Leishmaniasis (Peru-PK)

NCT01032382 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

30

Enrollment

FED

Sponsor class

Conditions

Leishmaniasis, Cutaneous

Interventions

DRUG: WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)
DRUG: Paromomycin Alone Cream (15% paromomycin topical cream)

Sponsor

U.S. Army Medical Research and Development Command